- Home
- IMUX vs NMI Comparison
IMUX vs NMI Comparison
Compare IMUX & NMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- NMI
- Stock Information
- Founded
- IMUX 2016
- NMI 1988
- Country
- IMUX United States
- NMI United States
- Employees
- IMUX N/A
- NMI N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- NMI Trusts Except Educational Religious and Charitable
- Sector
- IMUX Health Care
- NMI Finance
- Exchange
- IMUX Nasdaq
- NMI Nasdaq
- Market Cap
- IMUX 100.0M
- NMI 96.1M
- IPO Year
- IMUX N/A
- NMI N/A
- Fundamental
- Price
- IMUX $1.07
- NMI $9.54
- Analyst Decision
- IMUX Strong Buy
- NMI
- Analyst Count
- IMUX 6
- NMI 0
- Target Price
- IMUX $12.67
- NMI N/A
- AVG Volume (30 Days)
- IMUX 885.0K
- NMI 28.4K
- Earning Date
- IMUX 02-20-2025
- NMI 01-01-0001
- Dividend Yield
- IMUX N/A
- NMI 4.10%
- EPS Growth
- IMUX N/A
- NMI N/A
- EPS
- IMUX N/A
- NMI N/A
- Revenue
- IMUX N/A
- NMI N/A
- Revenue This Year
- IMUX N/A
- NMI N/A
- Revenue Next Year
- IMUX N/A
- NMI N/A
- P/E Ratio
- IMUX N/A
- NMI N/A
- Revenue Growth
- IMUX N/A
- NMI N/A
- 52 Week Low
- IMUX $0.97
- NMI $8.30
- 52 Week High
- IMUX $2.11
- NMI $10.05
- Technical
- Relative Strength Index (RSI)
- IMUX 45.08
- NMI 52.76
- Support Level
- IMUX $0.99
- NMI $9.37
- Resistance Level
- IMUX $1.09
- NMI $9.51
- Average True Range (ATR)
- IMUX 0.06
- NMI 0.10
- MACD
- IMUX -0.00
- NMI 0.01
- Stochastic Oscillator
- IMUX 39.89
- NMI 73.53
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.